龟鹿二仙胶巴布剂辅助治疗大肠癌患者化疗后骨髓抑制的临床观察

Adjuvant Function of Guilu Erxian Glue Cataplasm in Treating Carcinoma of the Large Intestine Patients with Myelosuppression after Chemotherapy:a Clinical Observation

目的观察龟鹿二仙胶巴布剂治疗大肠癌患者化疗后骨髓抑制的临床疗效,进一步论证其有效性和安全性。方法将60例大肠癌患者使用随机方法分为两组,同时采用FOLFIRI方案化疗。治疗组在化疗同时使用龟鹿二仙胶巴布剂外敷神阙穴,隔日更换1次,连用14天;对照组使用安慰剂,用法用量同治疗组。观察化疗前及化疗第7、10、14天WBC、NE、PLT计数,化疗前及化疗第7、14天中医症状积分、Karnofsky评分(KPS评分)及肝、肾功能,每天观察皮肤不良反应。并记录造血生长因子使用情况。结果(1)化疗后第7天治疗组KPS评分稳定率高于对照组,第14天治疗组外周血WBC、NE计数高于对照组、中医症状积分低于对照组,差异均有统计学意义(P<0.05);(2)治疗组PLT计数高于对照组、使用重组人粒细胞集落刺激因子(rhG-CSF)及抗生素均少于对照组,但差异无统计学意义(P>0.05)。(3)未见明显的肝、肾功能损伤,皮肤过敏等不良反应。结论龟鹿二仙胶巴布剂辅助治疗在一定程度上改善大肠癌化疗患者的骨髓抑制状况,未发现与其相关的不良反应。

Objective To observe the clinical effect of Guilu Erxian Glue Cataplasm （GEGC） on carcinoma of the large intestine patients with myelosuppression after chemotherapy, and further to con- firm its efficiency and safety. Methods Totally 60 patients with carcinoma of the large intestine were ran- domly assigned to two groups. Meanwhile, they all accepted FOLFIRI chemotherapy. Patients in the treat- ment group were additionally applied at Shenque （RN8）, exchanging once per every other day, for 14 successive days. Patients in the control group took placebos with the same dose and dosage as the treat- ment group. The blood cell counts （WBC, NE, and PLT） were detected before chemotherapy, at day 7, 10, and 14. The TCM symptoms integrals, Karnofsky performance score （KPS）, liver and kidney func- tions were observed before chemotherapy, at day 7 and day 14. Adverse skin reactions were observed each day. And the usage of hematopoietic growth factors was recorded. Results （1） The KPS score at day 7 was more stable in the treatment group than in the control group; the WBC and NE counts in the pe- ripheral blood at day 14 were higher in the treatment group than in the control group; and TCM symptoms integrals at day 14 was lower in the treatment group than in the control group, all with statistical differ- ence （P 〈0.05）. （2） Compared with the control group, the PLT count was higher in the treatment group than in the control group, the usage of rhG-CSF and antibiotics was less in the treatment group than in the control group, all with no statistical difference （P 〉0.05）. （3） No obvious adverse reactions such as liver injury, renal injury, or skin allergy were observed. Conclusions Adjuvant treatment of GEGC could im- prove carcinoma of the large intestine patients with myelosuppression to some extent. No relevant ad- verse reactions were found.